01—Abstract
Summary
Summary of the 8-K filed September 17, 2024. Cited figures are marked; the original filing is the authoritative source.
Philip Morris International Inc. (PM) has announced the sale of its subsidiary, Vectura Group Ltd., and its subsidiaries to Molex Asia Holdings Ltd. This strategic divestiture of its Vectura inhalation and respiratory drug delivery business is for an upfront cash consideration of approximately $198 milliona, with potential additional deferred payments of up to approximately $195 million contingent on future milestones extending to 2039.
The transaction is anticipated to close by the end of 2024, pending regulatory approvals and other customary conditions. This sale is expected to result in an estimated loss of approximately $220 millionb for PM in the third quarter of 2024, before customary adjustments. While this divestiture may impact near-term earnings due to the recognized loss, it signals PM's continued focus on streamlining its portfolio and potentially reallocating capital towards its core reduced-risk products and growth initiatives.
02—Key points
Key Highlights
- PM to sell Vectura Group Ltd. and its subsidiaries to Molex Asia Holdings Ltd.
- Upfront cash consideration of GBP 150 million (approx. $198 million), subject to adjustments.
- Potential for up to GBP 148 million (approx. $195 million) in deferred payments based on future milestones through 2039.
- Transaction expected to close by the end of 2024, subject to regulatory and closing conditions.
- Estimated loss of approximately $220 million to be recorded in Q3 2024 related to the sale.
- Divestiture of the inhalation and respiratory drug delivery business.
03—Questions
Frequently Asked Questions
What is Philip Morris International selling and to whom?
Philip Morris International is selling its wholly-owned subsidiary, Vectura Group Ltd., along with its subsidiaries, to Molex Asia Holdings Ltd. This business is focused on inhalation and respiratory drug delivery.
What is the financial impact of this sale on Philip Morris International?
The sale is expected to result in an estimated loss of approximately $220 million for Philip Morris International in the third quarter of 2024. This figure is subject to customary adjustments.
When is the sale expected to be completed?
The transaction is anticipated to close by the end of 2024, provided that regulatory approvals and other customary closing conditions are met.
What is the total potential value of this transaction?
The transaction includes an upfront cash payment of approximately $198 million, plus potential deferred payments of up to approximately $195 million contingent on the achievement of certain milestones over the next 15 years (through 2039).
04—Continue